94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
BRIEF RESEARCH REPORT article
Front. Pharmacol.
Sec. Pharmacogenetics and Pharmacogenomics
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1505490
This article is part of the Research Topic Editor's Feature: Negative Findings in Pharmacogenetics and Pharmacogenomics Volume II View all 5 articles
Effect of CYP3A5 Genotypes on pharmacokinetic of tacrolimus in Colombian liver transplant patients
Provisionally accepted
Jefferson Antonio Buendia *
Erica Fernanda Lindarte 
Luis Guillermo Toro Rendon 
Andrés Felipe Zuluaga Salazar - University of Antioquia, Medellín, Colombia
Background: Previous studies have reported a reduced tacrolimus dose-adjusted exposure in individuals expressing the CYP3A5*1 allele (rs 776746). However, information regarding Colombian liver transplantation patients is scarce. This study aimed to investigate the influence of CYP3A5 polymorphism on tacrolimus (TAC) pharmacokinetics in Colombian liver transplant patients.Methods: This was a prospective, single-center, open-label, pharmacogenetic study in stable adult liver transplant recipients followed up between 2020 and 2022. To evaluate the longitudinal relationship between the Co/doses, dose, and Co and CYP3A5 polymorphisms, a generalized estimating equations model was used using a log-gamma distribution.Results: We evaluated 16 patients who received TAC during the first two years after transplantation. CYP3A5*1 expression was observed 28% of patients. Patients with CYP3A5 expressors displayed lower C0 and C0/dose ratio and higher doses than those no expressors.We observed a lower C0/dose ratio in expresser recipients over two years of follow-up.Conclusions: The expression of CYP3A5 in stable liver transplant patient appeared to have the greatest influence on tacrolimus pharmacokinetics over the first two years posttransplant
Keywords: Tacrolimus, CYP3A5 polymorphisms, liver transplant, Colombia, Pharmacogenenomics and personalised medicine
Received: 03 Oct 2024; Accepted: 19 Feb 2025.
Copyright: © 2025 Buendia, Lindarte, Toro Rendon and Zuluaga Salazar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jefferson Antonio Buendia, University of Antioquia, Medellín, Colombia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.